JP2009530359A - 腫瘍成長の阻害 - Google Patents
腫瘍成長の阻害 Download PDFInfo
- Publication number
- JP2009530359A JP2009530359A JP2009500919A JP2009500919A JP2009530359A JP 2009530359 A JP2009530359 A JP 2009530359A JP 2009500919 A JP2009500919 A JP 2009500919A JP 2009500919 A JP2009500919 A JP 2009500919A JP 2009530359 A JP2009530359 A JP 2009530359A
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- growth
- peptide
- subject
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004614 tumor growth Effects 0.000 title abstract description 9
- 230000005764 inhibitory process Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 207
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 75
- 150000001875 compounds Chemical class 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 35
- 201000011510 cancer Diseases 0.000 claims abstract description 16
- 230000004721 adaptive immunity Effects 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 230000002101 lytic effect Effects 0.000 claims description 30
- 230000012010 growth Effects 0.000 claims description 26
- 208000011581 secondary neoplasm Diseases 0.000 claims description 14
- 230000028993 immune response Effects 0.000 claims description 12
- 230000006037 cell lysis Effects 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 230000017066 negative regulation of growth Effects 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 3
- 230000009036 growth inhibition Effects 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 24
- 238000011282 treatment Methods 0.000 abstract description 16
- -1 soluble peptides Chemical class 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 36
- 239000000427 antigen Substances 0.000 description 30
- 102000036639 antigens Human genes 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 30
- 210000004881 tumor cell Anatomy 0.000 description 22
- 230000009089 cytolysis Effects 0.000 description 21
- 210000000987 immune system Anatomy 0.000 description 20
- 230000036039 immunity Effects 0.000 description 9
- 210000004989 spleen cell Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000006054 immunological memory Effects 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000008029 eradication Effects 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003256 environmental substance Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- USSYUMHVHQSYNA-SLDJZXPVSA-N indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-SLDJZXPVSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical group C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0605685.7A GB0605685D0 (en) | 2006-03-21 | 2006-03-21 | Inhibition of tumour growth |
| PCT/GB2007/000993 WO2007107748A2 (en) | 2006-03-21 | 2007-03-21 | Inhibition of tumour growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009530359A true JP2009530359A (ja) | 2009-08-27 |
| JP2009530359A5 JP2009530359A5 (OSRAM) | 2010-05-06 |
Family
ID=36383910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500919A Pending JP2009530359A (ja) | 2006-03-21 | 2007-03-21 | 腫瘍成長の阻害 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2010204A2 (OSRAM) |
| JP (1) | JP2009530359A (OSRAM) |
| CN (1) | CN101466391A (OSRAM) |
| AU (1) | AU2007228574B2 (OSRAM) |
| CA (1) | CA2646589C (OSRAM) |
| GB (1) | GB0605685D0 (OSRAM) |
| NO (1) | NO20084053L (OSRAM) |
| WO (1) | WO2007107748A2 (OSRAM) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016128399A (ja) * | 2014-12-11 | 2016-07-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
| JP2016145183A (ja) * | 2014-12-11 | 2016-08-12 | リティックス バイオファーマ エイエス | 化学療法の組み合わせ |
| JP2017506629A (ja) * | 2014-02-04 | 2017-03-09 | ウニベルシテテット イ トロムソ−ノルゲス アークティスク ウニベルシテット | 抗リンパ腫ペプチド |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0821616D0 (en) * | 2008-11-26 | 2008-12-31 | Lytix Biopharma As | Compounds |
| CA2976377A1 (en) * | 2015-02-12 | 2016-08-18 | The Johns Hopkins University | Inhibition of yap for breaking tumor immune tolerance |
| GB201601868D0 (en) | 2016-02-02 | 2016-03-16 | Lytix Biopharma As | Methods |
| EP4637800A1 (en) | 2022-12-20 | 2025-10-29 | Lytix Biopharma AS | Compositions comprising an oncolytic peptide and chitosan |
| WO2024133580A1 (en) | 2022-12-20 | 2024-06-27 | Lytix Biopharma As | Medical products containing an aqueous formulation of a peptide |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995027497A1 (en) * | 1994-04-08 | 1995-10-19 | Demeter Biotechnologies, Ltd. | Method of combating mammalian neoplasia, and lytic peptides therefor |
| JP2002523517A (ja) * | 1998-08-28 | 2002-07-30 | アルファーマ エイ エス | 生物活性ペプチド |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861478A (en) * | 1987-07-06 | 1999-01-19 | Helix Biomedix, Inc. | Lytic peptides |
| DE3854476T2 (de) * | 1987-07-06 | 1996-04-04 | Univ Louisiana State | Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden. |
| US5773413A (en) * | 1993-06-04 | 1998-06-30 | Demeter Biotechnologies, Ltd. | Method of combating mammalian neoplasias, and lytic peptides therefor |
-
2006
- 2006-03-21 GB GBGB0605685.7A patent/GB0605685D0/en not_active Ceased
-
2007
- 2007-03-21 JP JP2009500919A patent/JP2009530359A/ja active Pending
- 2007-03-21 CN CNA2007800154351A patent/CN101466391A/zh active Pending
- 2007-03-21 WO PCT/GB2007/000993 patent/WO2007107748A2/en not_active Ceased
- 2007-03-21 AU AU2007228574A patent/AU2007228574B2/en not_active Ceased
- 2007-03-21 CA CA2646589A patent/CA2646589C/en not_active Expired - Fee Related
- 2007-03-21 EP EP07732085A patent/EP2010204A2/en not_active Withdrawn
-
2008
- 2008-09-24 NO NO20084053A patent/NO20084053L/no not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995027497A1 (en) * | 1994-04-08 | 1995-10-19 | Demeter Biotechnologies, Ltd. | Method of combating mammalian neoplasia, and lytic peptides therefor |
| JP2002523517A (ja) * | 1998-08-28 | 2002-07-30 | アルファーマ エイ エス | 生物活性ペプチド |
Non-Patent Citations (2)
| Title |
|---|
| JPN6012028539; 清水敬生， ｅｔ ａｌ．: '人感染型ｖｉｒｕｓを用いた眼特異的免疫治療モデルにおけるプライミングの意義' 日本癌治療学会誌 Ｖｏｌ． ２４， Ｎｏ． ５, 198905, ｐ． １００７-１０１４ * |
| JPN6012028542; Ｅｌｉａｓｓｅｎ ＬＴ， ｅｔ ａｌ．: 'Ｅｎｈａｎｃｅｄ ａｎｔｉｔｕｍｏｕｒ ａｃｔｉｖｉｔｙ ｏｆ １５-ｒｅｓｉｄｕｅ ｂｏｖｉｎｅ ｌａｃｔｏｆｅｒｒｉｃｉｎ ｄｅｒｉｖａｔｉｖｅｓ ｃｏｎｔａｉｎｉｎｇ ｂｕｌｋｙ ａｒｏｍａｔｉ' Ｊｏｕｒｎａｌ ｏｆ Ｐｅｐｔｉｄｅ Ｓｃｉｅｎｃｅ Ｖｏｌ． ９， Ｎｏ． ８, 200308, ｐ． ５１０-５１７ * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017506629A (ja) * | 2014-02-04 | 2017-03-09 | ウニベルシテテット イ トロムソ−ノルゲス アークティスク ウニベルシテット | 抗リンパ腫ペプチド |
| JP2016128399A (ja) * | 2014-12-11 | 2016-07-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
| JP2016145183A (ja) * | 2014-12-11 | 2016-08-12 | リティックス バイオファーマ エイエス | 化学療法の組み合わせ |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007107748A3 (en) | 2007-12-06 |
| GB0605685D0 (en) | 2006-05-03 |
| AU2007228574A1 (en) | 2007-09-27 |
| NO20084053L (no) | 2008-11-28 |
| EP2010204A2 (en) | 2009-01-07 |
| AU2007228574B2 (en) | 2013-06-20 |
| WO2007107748A2 (en) | 2007-09-27 |
| CA2646589C (en) | 2016-05-03 |
| CA2646589A1 (en) | 2007-09-27 |
| CN101466391A (zh) | 2009-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007228574B2 (en) | Inhibition of tumour growth | |
| ES2819282T3 (es) | Combinaciones de inhibidores de puntos de control inmunitarios | |
| CN105939723B (zh) | 前列腺癌治疗用组合物 | |
| ES2460899T3 (es) | Inmunoterapia basada en células cancerosas alógenas | |
| US12161688B2 (en) | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells | |
| RU2448729C2 (ru) | Композиции, вызывающие специфический ответ цитотоксических т-лимфоцитов, включающие лимфо-аблативное соединение и молекулу, содержащую антигенные последовательности и нацеленную на специализированные антиген-презентирующие клетки | |
| CN107921106A (zh) | Wt1抗原肽和免疫调节剂的组合 | |
| KR20120098919A (ko) | 암의 치료제 | |
| HUT74425A (en) | A method for sensitization of cancer for killer cell mediated lysis | |
| US20250002854A1 (en) | Methods of generating populations of tumour-infiltrating t cells | |
| EP1712238A1 (en) | Anthracyclin induced immunogenic dead or dying cells composition | |
| US9109048B2 (en) | Inhibition of tumor growth | |
| Najar et al. | Topical CpG enhances the response of murine malignant melanoma to dacarbazine | |
| WO2016071431A1 (en) | A combination for cancer therapy | |
| WO2021085696A1 (ko) | 작은 지질 나노 입자 및 이를 포함하는 암 백신 | |
| CA3221194A1 (en) | Immuno-oncology therapeutic composition using adjuvant including lipopeptides and poly (i:c) | |
| Fidler | Therapy of disseminated melanoma by liposome‐activated macrophages | |
| EP2667880B1 (en) | Metalloproteinase oligopeptides and their therapeutic use | |
| JP7242059B2 (ja) | シェーグレン症候群の治療用ペプチド | |
| JP7522770B2 (ja) | 術後補助療法剤 | |
| EP4420677A1 (en) | Vaccines against tert-positive tumors | |
| US11123398B2 (en) | Chemotherapeutic combinations of cationic antimicrobial peptides and chemotherapeutics | |
| CN105263502A (zh) | 包含gpg寡脱氧核苷酸和环状二gmp的药物组合物 | |
| Zhou et al. | Blocking Blood Supply to Breast Carcinoma With a DNA Vaccine Encoding VEGF Receptor-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100319 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100319 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20120229 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120501 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120605 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120830 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120906 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121204 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130212 |